JPMorgan cuts target for Sotera Health stock from USD 18 to USD 17
Published on 10/20/2026 at 18:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting date
- JPMorgan cut its Sotera Health target from USD 18.00 to USD 17.00 on October 14, 2026.
- Second-quarter revenue reached USD 321.38 million for the period ended June 30, 2026.
- Sotera Health stock was at EUR 16.00 at Lang & Schwarz on October 20, 2026 at 6:48 p.m. CEST.
- The company is scheduled to report third-quarter 2026 results on November 3, 2026.
Sotera Health stock became the subject of a JPMorgan downgrade on October 14, 2026, when the bank moved its rating from Neutral to Underweight and cut its target from USD 18.00 to USD 17.00, as Markets Insider reported. At Lang & Schwarz, the stock was trading at EUR 16.00 on October 20, 2026 at 6:48 p.m. CEST.
Revenue growth remains visible
The company reported second-quarter 2026 revenue of USD 321.38 million for the period ended June 30, 2026, up 9.20 percent from the prior-year quarter. Net income reached USD 53.64 million, or USD 0.19 per diluted share, compared with USD 8.00 million and USD 0.03 per diluted share in the second quarter of 2025, according to Sotera Health.
Stock position and valuation
The Nasdaq quote stood at USD 17.98 on October 20, 2026 at 12:57 p.m. ET. Sotera Health had a market capitalization of USD 5.1 billion and a trailing price-to-earnings ratio of 31.43 at that timestamp. Its 52-week range was USD 13.09 to USD 19.85, placing the quote 9.42 percent below the high and 37.36 percent above the low. Trading volume reached 590,875 shares.
Target and reporting date matter
JPMorgan's USD 17.00 target stood 5.45 percent below the Nasdaq price of USD 17.98 on October 20, 2026. The bank cited uncertainty around future volume growth and the medical device end market in its October 14 note, as Markets Insider reported. Sotera Health is scheduled to report third-quarter 2026 results on November 3, 2026, with consensus earnings per share of USD 0.24, according to MetaCap.
Peer valuation stays mixed
Comparison with peers
Progyny (Nasdaq, USD): down 2.17 percent, P/E 29.80, market capitalization USD 2.06 billion, according to MetaCap.
DaVita (NYSE, USD): down 0.98 percent, P/E 15.80, market capitalization USD 11.95 billion, according to MetaCap.
What the target signals
The lower JPMorgan target contrasts with Sotera Health's 9.20 percent second-quarter revenue growth and sets a clear test for the November results. Investors will have fresh operating figures to compare with the USD 17.00 target.
On Nasdaq, the stock was trading at USD 17.98 on October 20, 2026 at 12:57 p.m. ET. The further course of trading is shown by the continuously updated real-time quote of Sotera Health stock.
Sotera Health at a glance
- Company: Sotera Health Company
- ISIN: US83601L1026
- Ticker: SHC
- Primary exchange: Nasdaq
- Price Lang & Schwarz as of October 20, 2026, 6:48 p.m. CEST: EUR 16.00
- Market capitalization: USD 5.1 billion as of October 20, 2026
- 52-week range: USD 13.09-19.85 as of October 20, 2026
- Sector / Industry: Health Care / Miscellaneous Health and Biotechnology Services
- Next earnings date: November 3, 2026
Market context: Market report S&P 500.
